精功科技(002006.SZ):擬5000萬元參投私募基金 主投低碳科技、硬科技、醫療科技領域成長期及早期項目
格隆匯2月21日丨精功科技(002006.SZ)公佈,為進一步優化公司投資結構,提高資金使用效率和投資收益水平,加快推動公司“碳纖維裝備、碳中和(新能源)裝備”等核心業務發展,提升公司綜合競爭力,同意公司與普通合夥人杭州光速晟遠企業管理諮詢合夥企業(有限合夥)簽署《杭州光合貳期創業投資合夥企業(有限合夥)有限合夥協議》,同意公司利用自有資金5000萬元作為有限合夥人認購杭州光合貳期創業投資合夥企業(有限合夥)份額,該基金主要投資於低碳科技、硬科技、醫療科技領域的成長期及早期項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.